ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Shares Acquired by Raymond James & Associates

Posted by Defense World Staff on Nov 15th, 2023

Raymond James & Associates lifted its holdings in shares of ThermoGenesis Holdings, Inc. (NASDAQ:THMO – Free Report) by 100.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,004 shares of the company’s stock after buying an additional 25,000 shares during the quarter. Raymond James & Associates owned approximately 2.63% of ThermoGenesis worth $64,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Jane Street Group LLC acquired a new position in shares of ThermoGenesis during the 1st quarter worth approximately $37,000. Armistice Capital LLC acquired a new position in shares of ThermoGenesis during the 1st quarter worth approximately $328,000. Two Sigma Securities LLC acquired a new position in shares of ThermoGenesis during the 1st quarter worth approximately $37,000. Two Sigma Investments LP acquired a new position in shares of ThermoGenesis during the 1st quarter worth approximately $40,000. Finally, Renaissance Technologies LLC acquired a new position in shares of ThermoGenesis during the 1st quarter worth approximately $42,000. 4.71% of the stock is owned by institutional investors and hedge funds.

ThermoGenesis Trading Down 17.9 %

Shares of THMO opened at $0.99 on Wednesday. ThermoGenesis Holdings, Inc. has a one year low of $0.90 and a one year high of $6.75. The stock has a 50 day moving average price of $1.14 and a 200 day moving average price of $1.31.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of ThermoGenesis in a research report on Tuesday.

Read Our Latest Analysis on THMO

About ThermoGenesis

(Free Report)

ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.